Clinical Characteristic Myasthenia Gravis among Indonesians
Abstract
Myasthenia gravis (MG) is a relatively rare autoimmune disorder on peripheral nerves where an antibody of nicotinic acetylcholine postsynaptic receptor is formed on neuromuscular junction (NMJ). MG is clinically characterized with a fluctuating muscle weakness. The incidence rate is 0.25 to 2.0 per 1,000,000 among population. 10% of the population is children and adolescents. Over the past forty years, a mortality rate has improved in the myasthenic crisis from 75% to less than 5%. Moreover, in Indonesia, this is still considered a rare disease. This study applied a retrospective cross-sectional study design. Data were gathered from patients diagnosed and treated for myasthenia gravis admitted in the neurological emergencies in the hospital during January to November 2019. Afterwards, the follow-up clinical information was also being analyzed. 12 cases of myasthenia gravis were collected with females predominated (75%), and one male (25%) with the average age of 30-40 years. The majority (75%) had the onset of < 35 years. The patients were from various districts, with 75% referral from the district and 58% housewives. Clinically, 8% patients had the ocular myasthenia and 92% was the generalized one. The ocular myasthenia had a relatively earlier onset. As MG symptomatology bears a wide range of variability and severity, it was graded based on Osserman’s and Myasthenia Gravis Foundation of America’s (MGFA) classification. Out of all patients, 13.7% belonged to Osserman’s class 1-3 (33%) and class 4-5 (67%). Myasthenia Gravis Foundation of America (MGFA) grading calibrated the severity of each crisis. The findings were 17% crisis of milder degree and 83% of moderate to severe nature. The thyroid disorder was evident in one of the patients (8.3%). Laboratory findings were 75% patients with the increase in leukocyte count. The treatment was only 25% anticholinesterase, 50% anticholinesterase and steroid, in addition to 25% anticholinesterase and therapeutic plasma exchange (TPE). The hospital stay was (the average in days) 83% with >7 days. The myasthenia gravis reported was 12 cases. Patients’ outcome depended on the clinical condition when they first arrived in the hospital. These findings will be useful for the resource allocation and planning in health services. Many regions worldwide have few or no epidemiological data on the myasthenia gravis, and more studies are required to yield more estimates that are accurate.
Keywords
Full Text:
PDFReferences
Achiron A, Barak Y, Miron S, et al. Immunoglobulin treatment in refractory myasthenia gravis. Muscle Nerve 2000;23(4):551–5.
Burns et al. Myasthenia Gravis. In Netter`s Neurology2nd Edition. 2012; 73: 684-702.
Benatar M, McDermott MP, Sanders DB, et al. Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial. Muscle Nerve 2016;53(3):363–9.
Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010;10:46.
Dalkas MC. Immunotherapy in myasthenia gravies in the era of biologics. Nat Rev Neurol. 2019;15:113–24.
Drachman DB. Myasthenia Gravis and Other Diseases of The Neuromuscular Junction Kasper. In: Braunwald, Fauci, Hauser, Longo, Jameson. Harrison’s : Principle of Internal Medicine 18th ed. McGraw Hill. 2012; 366: 2523-2518.
Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of Myasthenia Gravis. Neurol Clin. 2018;36(2):311‐337. doi:10.1016/j.ncl.2018.01.011
Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 2002;(4):CD002275.
Gilhus NE, Verschuuren JJ. Myasthenia gravis: Subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14:1023–36
Hemminki K, Li X, Sundquist K. Familial risks for diseases of myoneural junction and muscle in siblings based on hospitalizations and deaths in sweden. Twin Res Hum Genet. 2006;9:573–579. doi: 10.1375/twin.9.4.573
International MG/COVID-19 Working Group, Jacob S, Muppidi S, et al. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020;412:116803.
Jaretzki AR, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg. 2000;70:327–334. doi: 10.1016/S0003-4975(00)01595-2.
Kupersmith MJ, Ying G. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol 2005;89(10):1330–4.
Li KK, Qian K, Feng YG, Guo W, Tan QY, Deng B. Predictive factors of prolonged mechanical ventilation, overall survival, and quality of life in patients with post-thymectomy myasthenic crisis. World J Surg Oncol. 2017;15(1):150. Published 2017 Aug 8. doi:10.1186/s12957-017-1209-1
Liew WK, Powell CA, Sloan SR, et al. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA Neurol 2014;71(5):575–80.
Leuzzi G, Meacci E, Cusumano G, Cesario A, Chiappetta M, Dall'Armi V, Evoli A, Costa R, Lococo F, Primieri P, et al. Thymectomy in myasthenia gravis: proposal for a predictive score of postoperative myasthenic crisis. Eur J Cardiothorac Surg 2014; 45:e76-88, e88.
Murthy JMK. Myasthenia Gravis: Do the Subtypes Matter? Ann Indian Acad Neurol. 2020 Jan-Feb;23(1):2. doi: 10.4103/aian.AIAN_595_19. Epub 2020 Jan 21. PMID: 32055109;
Melzer N, Ruck T, Fuhr P, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol. 2016;263(8):1473‐1494. doi:10.1007/s00415-016-8045-z
Mittal MK, Barohn RJ, Pasnoor M, et al. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response. J Clin Neuromuscul Dis 2011;13(1):46–52.
Romi F. Thymoma in myasthenia gravis: From diagnosis to treatment. Autoimmune Dis. 2011;2011:474512.
Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012;78(13):1009–15.
Proudfoot A The early toxicology of physostigmine: a tale of beans, great men and egos. Toxicol Rev 2006;25(2):99–138.
Robertson NP, Deans J, Compston DA. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry. 1998;65:492–496. doi: 10.1136/jnnp.65.4.492.
Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology 2016; 87(4):419–25.
Statland JM, Ciafaloni E. Myasthenia gravis: Five new things. Neurol Clin Pract. 2013;3(2):126‐133. doi:10.1212/CPJ.0b013e31828d9fec
Wolfe GI, Barohn RJ, Foster BM, et al. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 2002;26(4):549–52.
DOI: https://doi.org/10.33258/birex.v2i2.1015
Article Metrics
Abstract view : 574 timesPDF - 379 times
Refbacks
- There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.